For example, pharmacy benefit manager CVS Caremark indicated it will no longer cover insulin brand Lantus, and will instead cover a new biosimilar to the drug, called Basaglar.
Prices for many insulin brands have increased in recent years. According to drug discount search company GoodRx, prices for Lantus increased about 60 percent, from $240 to $380, between January 2013 and October 2016, USA Today reports. Humalog and many other insulin brands have risen from about $300 to $500.
Troyven Brennan, MD, a physician and chief health officer at CVS Caremark, said patients who have a bad reaction to a change in insulin can request an exception to the new formulary, according to the report.
More articles on supply chain:
Value-based supply chain management: 5 questions with Cardinal Health’s Carola Endicott and Ken Shastany
FDA shoots down Cempra’s antibiotic for pneumonia
FDA warns hospitals of battery-powered medical cart fires, explosions
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
